Rho激酶抑制剂法舒地尔对离体羊逼尿肌收缩力的抑制和关酰环化酶抑制剂ODQ的逆转

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Niranjana Jeba Jeeviha MD, Aniket Kumar PhD, Rohini Ann Mathew MD, Silvia Joseph MD, Mohammed Haris MSc, Margaret Shanthi MD, Jacob Peedicayil MD
{"title":"Rho激酶抑制剂法舒地尔对离体羊逼尿肌收缩力的抑制和关酰环化酶抑制剂ODQ的逆转","authors":"Niranjana Jeba Jeeviha MD,&nbsp;Aniket Kumar PhD,&nbsp;Rohini Ann Mathew MD,&nbsp;Silvia Joseph MD,&nbsp;Mohammed Haris MSc,&nbsp;Margaret Shanthi MD,&nbsp;Jacob Peedicayil MD","doi":"10.1016/j.curtheres.2025.100795","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Rho kinase (also called rho-associated protein kinase or ROCK), a serine/threonine kinase, is involved in muscle contractility since it phosphorylates myosin light chain phosphatase, hence inhibiting it. This leads to enhanced muscle contractility. Fasudil is an inhibitor of rho kinase that has been approved for the treatment of cerebral vasospasm in some Asian countries.</div></div><div><h3>Objective</h3><div>In this study, we tested the ability of fasudil to inhibit the contractility of the isolated caprine (goat) detrusor.</div></div><div><h3>Methods</h3><div>Twelve caprine detrusor strips were contracted using 80 mM KCl before and after the administration of 3 concentrations (10, 30, and 60 µM) of fasudil. Two reversal agents, the guanylyl cyclase inhibitor ODQ (10 µm) and the P2X receptor agonist diadenosine pentaphosphate (DAPP) (10 µM), were tested for their ability to reverse the inhibitory effect of fasudil on isolated detrusor contractility.</div></div><div><h3>Results</h3><div>Fasudil caused a dose-dependent inhibitory effect of KCl-induced detrusor contractility that was statistically significant at 30 and 60 µM concentrations. The inhibitory effect of 30 µM fasudil on detrusor contractility was significantly reversed by the addition of ODQ, but not by the addition of DAPP.</div></div><div><h3>Conclusions</h3><div>These results suggest that fasudil inhibits the contractility of the isolated detrusor. Fasudil could be investigated for use in clinical conditions such as overactive bladder that require detrusor muscle relaxation.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100795"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inhibition of Contractility of Isolated Caprine Detrusor by the Rho Kinase Inhibitor Fasudil and Reversal by the Guanylyl Cyclase Inhibitor ODQ\",\"authors\":\"Niranjana Jeba Jeeviha MD,&nbsp;Aniket Kumar PhD,&nbsp;Rohini Ann Mathew MD,&nbsp;Silvia Joseph MD,&nbsp;Mohammed Haris MSc,&nbsp;Margaret Shanthi MD,&nbsp;Jacob Peedicayil MD\",\"doi\":\"10.1016/j.curtheres.2025.100795\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Rho kinase (also called rho-associated protein kinase or ROCK), a serine/threonine kinase, is involved in muscle contractility since it phosphorylates myosin light chain phosphatase, hence inhibiting it. This leads to enhanced muscle contractility. Fasudil is an inhibitor of rho kinase that has been approved for the treatment of cerebral vasospasm in some Asian countries.</div></div><div><h3>Objective</h3><div>In this study, we tested the ability of fasudil to inhibit the contractility of the isolated caprine (goat) detrusor.</div></div><div><h3>Methods</h3><div>Twelve caprine detrusor strips were contracted using 80 mM KCl before and after the administration of 3 concentrations (10, 30, and 60 µM) of fasudil. Two reversal agents, the guanylyl cyclase inhibitor ODQ (10 µm) and the P2X receptor agonist diadenosine pentaphosphate (DAPP) (10 µM), were tested for their ability to reverse the inhibitory effect of fasudil on isolated detrusor contractility.</div></div><div><h3>Results</h3><div>Fasudil caused a dose-dependent inhibitory effect of KCl-induced detrusor contractility that was statistically significant at 30 and 60 µM concentrations. The inhibitory effect of 30 µM fasudil on detrusor contractility was significantly reversed by the addition of ODQ, but not by the addition of DAPP.</div></div><div><h3>Conclusions</h3><div>These results suggest that fasudil inhibits the contractility of the isolated detrusor. Fasudil could be investigated for use in clinical conditions such as overactive bladder that require detrusor muscle relaxation.</div></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"102 \",\"pages\":\"Article 100795\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X25000207\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X25000207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

rho激酶(也称为rho相关蛋白激酶或ROCK)是一种丝氨酸/苏氨酸激酶,它使肌球蛋白轻链磷酸酶磷酸化,从而抑制肌球蛋白轻链磷酸酶,从而参与肌肉收缩。这可以增强肌肉的收缩力。法舒地尔是一种rho激酶抑制剂,在一些亚洲国家已被批准用于治疗脑血管痉挛。目的研究法舒地尔对离体山羊逼尿肌收缩力的抑制作用。方法法舒地尔给药前后分别用80 mM氯化钾收缩12条羊逼尿条。我们测试了两种逆转剂,即观乙酰环化酶抑制剂ODQ(10µm)和P2X受体激动剂二腺苷五磷酸(DAPP)(10µm),以逆转法舒地尔对离体逼尿肌收缩的抑制作用。结果法舒地尔对kcl诱导的逼尿肌收缩有剂量依赖性的抑制作用,在30和60µM浓度下具有统计学意义。30µM法舒地尔对逼尿肌收缩力的抑制作用被ODQ显著逆转,而不被DAPP逆转。结论法舒地尔能抑制离体逼尿肌的收缩力。法舒地尔可以研究用于临床条件,如膀胱过度活动,需要逼尿肌放松。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Inhibition of Contractility of Isolated Caprine Detrusor by the Rho Kinase Inhibitor Fasudil and Reversal by the Guanylyl Cyclase Inhibitor ODQ

Background

Rho kinase (also called rho-associated protein kinase or ROCK), a serine/threonine kinase, is involved in muscle contractility since it phosphorylates myosin light chain phosphatase, hence inhibiting it. This leads to enhanced muscle contractility. Fasudil is an inhibitor of rho kinase that has been approved for the treatment of cerebral vasospasm in some Asian countries.

Objective

In this study, we tested the ability of fasudil to inhibit the contractility of the isolated caprine (goat) detrusor.

Methods

Twelve caprine detrusor strips were contracted using 80 mM KCl before and after the administration of 3 concentrations (10, 30, and 60 µM) of fasudil. Two reversal agents, the guanylyl cyclase inhibitor ODQ (10 µm) and the P2X receptor agonist diadenosine pentaphosphate (DAPP) (10 µM), were tested for their ability to reverse the inhibitory effect of fasudil on isolated detrusor contractility.

Results

Fasudil caused a dose-dependent inhibitory effect of KCl-induced detrusor contractility that was statistically significant at 30 and 60 µM concentrations. The inhibitory effect of 30 µM fasudil on detrusor contractility was significantly reversed by the addition of ODQ, but not by the addition of DAPP.

Conclusions

These results suggest that fasudil inhibits the contractility of the isolated detrusor. Fasudil could be investigated for use in clinical conditions such as overactive bladder that require detrusor muscle relaxation.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
31
审稿时长
3 months
期刊介绍: We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信